Efficacy of Trametinib in Neurofibromatosis Type 1-Associated Gastrointestinal Stromal Tumors: A Case Report

JCO Precis Oncol. 2024 Aug:8:e2300649. doi: 10.1200/PO.23.00649.

Authors

Misao Fukuda¹, Toru Mukohara^{1

2}, Takeshi Kuwata², Kuniko Sunami³, Yoichi Naito^{1

4}

Affiliations

¹ Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
² Department of Genetic Medicine and Services, National Cancer Center Hospital East, Kashiwa, Japan.
³ Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan.
⁴ Department of General Internal Medicine, National Cancer Center Hospital East, Kashiwa, Japan.

Abstract

Trametinib, an MEK inhibitor, may offer a new therapeutic option for patients with NF1-related GIST.

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / therapeutic use
Female
Gastrointestinal Neoplasms / drug therapy
Gastrointestinal Stromal Tumors* / drug therapy
Humans
Male
Middle Aged
Neurofibromatosis 1* / complications
Neurofibromatosis 1* / drug therapy
Protein Kinase Inhibitors / therapeutic use
Pyridones* / therapeutic use
Pyrimidinones* / therapeutic use

Substances

trametinib
Pyridones
Pyrimidinones
Protein Kinase Inhibitors
Antineoplastic Agents